Nobilis Therapeutics leadership will be attending J.P.Morgan’s 36th Annual Healthcare Conference that will take place in San Francisco on January 8-11. If you are interested in setting up a f2f meeting with our team, please send us an email.
News
- Imminent Mental Health Crisis in America March 22, 2020
- Nobilis Therapeutics Supports Grant Application to IOCDF for an Investigator-initiated Clinical Trial of NBTX-001 in Patients with Obsessive-Compulsive Syndrome February 28, 2020
- Nobilis Therapeutics to attend 38th Annual J.P. MORGAN Healthcare Conference on January 13-16, 2020 January 3, 2020
- Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Posttraumatic Stress Disorder December 6, 2019
- Nobilis Therapeutics’ NBTX-001 Showed Beneficial Effects in an Animal Model of Autism December 3, 2019
Recent Posts
- Imminent Mental Health Crisis in America
- Nobilis Therapeutics Supports Grant Application to IOCDF for an Investigator-initiated Clinical Trial of NBTX-001 in Patients with Obsessive-Compulsive Syndrome
- Nobilis Therapeutics to attend 38th Annual J.P. MORGAN Healthcare Conference on January 13-16, 2020
- Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Posttraumatic Stress Disorder
- Nobilis Therapeutics’ NBTX-001 Showed Beneficial Effects in an Animal Model of Autism
Recent Comments